MPLT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MapLight Therapeutics Inc (MPLT) is not a compelling buy at the moment for a beginner investor with a long-term strategy. While analysts have a positive outlook and the technical indicators show bullish momentum, the lack of significant financial growth, absence of recent news catalysts, and neutral trading sentiment from insiders and hedge funds suggest limited immediate upside. Additionally, the stock's recent performance and projected short-term price movement do not align with a strong entry point for long-term gains.
The technical indicators show bullish momentum with a positively expanding MACD, RSI in the neutral zone, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The stock is trading above its key pivot level, with resistance levels at 21.059 and 22.348.
Analysts initiated coverage with a Buy rating and a $35 price target, citing undervaluation and potential in schizophrenia therapeutics. Phase 2 data for ML-007C-MA in schizophrenia, expected in Q3, could act as a future catalyst.
No significant trading trends from hedge funds or insiders. Financials show no revenue growth and a significant net loss (-$79.5M in Q4 2025). No recent news or congress trading activity.
In Q4 2025, the company reported no revenue growth (0% YoY), a net loss of -$79.5M, and an EPS of -18.56 (up 892.51% YoY). Gross margin remains at 0%.
Canaccord initiated coverage with a Buy rating and a $35 price target, highlighting the company's potential in central nervous system therapeutics, specifically schizophrenia.
